Trial Changes First-Line Approach for Most Common Breast Cancer Subtype

(MedPage Today) — CHICAGO — Incorporating the investigational, oral selective estrogen receptor degrader (SERD) camizestrant at the first sign of emerging ESR1 mutations extended the benefit of first-line therapy in hormone receptor (HR)-positive…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115837

Author :

Publish date : 2025-06-01 12:00:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30	31

Trial Changes First-Line Approach for Most Common Breast Cancer Subtype

Viral TikTok Trend for Weight Loss Is Harmful for Health

Which Class of ER Degrader Is Better?

Related Posts

‘My dad started spying on my mum’ – the drugs causing sexual urges

10,000 steps myth – should you be a stickler for recommended daily doses?

Why we need to talk about periods, breasts and injuries

Solar drone with wingspan wider than jumbo jet could fly for months

Study Touts Benefit of Mini Nonhormonal IUD — But It’s Not Sold in the U.S.

Negative social ties, like frenemies, could be ageing you

‘My dad started spying on my mum’ – the drugs causing sexual urges

10,000 steps myth – should you be a stickler for recommended daily doses?

Why we need to talk about periods, breasts and injuries

Solar drone with wingspan wider than jumbo jet could fly for months

Study Touts Benefit of Mini Nonhormonal IUD — But It’s Not Sold in the U.S.

Negative social ties, like frenemies, could be ageing you

Could Direct Primary Care’s Popularity Be on the Rise?

Will ‘Safe Staffing Committee’ Laws Help Reduce ED Wait Times?

Categories

Archives